A major regulatory milestone was achieved in November 2025 when Germany’s Federal Cartel Office (Bundeskartellamt) granted clearance for the takeover. BioNTech had initially announced the exchange ...
CureVac ( (CVAC)) just unveiled an update. On January 6, 2026, CureVac N.V. completed a post-offer reorganization tied to BioNTech SE’s exchange offer, resulting in BioNTech becoming the sole owner of ...
The publicly traded chapter for CureVac has closed. The biotechnology firm's shares have ceased trading and have been formally delisted from the Nasdaq exchange, marking the final step in its full ...
German Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an important step toward the expected closing later this year Offer ...
MAINZ, Germany, December 3, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that 184,071,410 shares of CureVac N.V. (Nasdaq: CVAC, “CureVac”), representing approximately 81.74% of ...
The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac’s issued and outstanding shares, tendered prior to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results